期刊文献+

急性髓系白血病患者外周血TK1和SPF的分析 被引量:4

TK1 and SPF in peripheral blood of acute myeloid leukemia patients
下载PDF
导出
摘要 目的探讨外周血胸腺嘧啶核苷激酶1(TK1)和S期细胞百分比(SPF)在急性髓系白血病(AML)诊断、疗效监测及预后中的意义。方法选取AML患者58例、血液系统良性增殖疾病患者(良性增殖组)6例和体检健康者(正常对照组)20名,采用印迹免疫-增强发光法检测TK1,采用流式细胞术(FCM)检测SPF。58例AML患者经1个疗程的标准诱导治疗后,比较治疗前、缓解组(39例,其中完全缓解11例、部分缓解28例)和未缓解组(19例)的TK1和SPF;同时检测58例AML患者治疗后1周和1个月的TK1和SPF。结果 AML组治疗前TK1为(2.43±1.02)pmol/L、SPF为(4.62±2.33)%,明显高于良性增殖组[TK1为(1.12±0.41)pmol/L、SPF为(2.62±1.05)%]及正常对照组[TK1为(0.39±0.15)pmol/L、SPF为(2.21±0.96)%](P<0.05)。AML完全缓解组TK1为(0.78±0.44)pmol/L、SPF为(1.89±1.23)%,明显低于治疗前和未缓解组[TK1为(4.26±0.46)pmol/L、SPF为(5.58±3.12)%](P<0.05)。AML患者治疗1个月后,TK1和SPF分别为(1.97±0.89)pmlol/L和(2.89±1.03)%,明显低于治疗前(P<0.05)。结论外周血TK1联合SPF检测能更准确地预测AML的细胞增殖情况,可很好地指示AML的治疗及提示预后。 ObjectiveTo evaluate thymidine kinase 1(TK1) and S-phase fraction(SPF) in peripheral blood for the diagnosis,treatment monitoring and prognosis of acute myeloid leukemia(AML). MethodsA total of 58 patients with AML were enrolled,and 6 patients with benign proliferative disease in hematological system and 20 healthy subjects were enrolled as well. TK1 levels were determined by dot-blot enhanced chemiluminescence,and SPF were calculated by ?ow cytometry. After a standard inductive treatment,the levels of TK1 and SPF were compared in remission group(39 cases,including 11 cases of complete remission and 28 cases of partial remission) and non-remission group(19 cases) with those before treatment. The levels of TK1 and SPF were determined at the time points of a week and a month after treatment. ResultsThe levels of TK1 [(2.43±1.02)pmol/L] and SPF[(4.62±2.33)%] in AML group before treatment were higher than those in benign proliferative disease group [(1.12±0.41)pmol/L and(2.62±1.05)%] and healthy control group[(0.39±0.15)pmol/L and(2.21±0.96)%](P〈0.05). The levels of TK1 [(0.78±0.44) pmol/L] and SPF [(1.89±1.23)%] decreased in complete remission group compared with those before treatment and in non-remission group [(4.26±0.46)pmol/L and(5.58±3.12)%](P〈0.05). After a standard inductive treatment for a month,the levels of TK1 [(1.97±0.89)pmol/L] and SPF [(2.89±1.03)%] were lower than those before treatment(P〈0.05). ConclusionsThe combined determination of TK1 and SPF is accurate for the proliferation status of AML and can indicate treatment and prognosis status of AML.
出处 《检验医学》 CAS 2017年第10期59-62,共4页 Laboratory Medicine
基金 武警后勤学院附属医院资助项目(FYM201615)
关键词 胸腺嘧啶核苷激酶1 S期细胞百分比 急性髓系白血病 Thymidine kinase 1 S-phase fraction Acute myeloid leukemia
  • 相关文献

参考文献8

二级参考文献52

  • 1宋华,郭淑芬,徐淑芝,汤永民厉华.用流式细胞仪测定小儿急性白血病细胞DNA及其临床意义研究[J].中华血液学杂志,1994,15(3):137-138. 被引量:9
  • 2朱勇梅,陈赛娟.微小残留病检测方法及其临床应用[J].中国实验血液学杂志,2005,13(6):1131-1136. 被引量:13
  • 3涂植光.依托现代科学管理和技术 开展肿瘤标志物研究和应用[J].中华检验医学杂志,2006,29(4):289-292. 被引量:15
  • 4张之南.血液病诊断及疗效标准.2版.北京:科学出版社,1999:168-179.
  • 5王永才 高学军 张辉.淋巴细胞微核及DNA异倍体对恶性肿瘤早期诊断研究应用.中华临床医药杂志,2001,13(15):2324-2326.
  • 6Aulc Germing,U Gattermann,N Minning.Increasing incidence of myelodyspl-astic syndromes:real or fictitious[J] Leuk Res,1998,22(1):93-100.
  • 7王永才.锌原卟啉(ZPP)和微核及DNA异倍体联合测定(积分法)对恶性肿瘤早期诊断研究.中华临床医药杂志,2002,10(10):1148-1150.
  • 8王永才等.微核测定和T细胞亚群在恶性血液病及癌肿诊断中作用的研究.中华临床医药杂志,2001,13(10):1464-1464.
  • 9王永才等.各种疾病外周血淋巴细胞微核四项检测指标临床应用.美国中华健康卫生杂志,2001,4(11):11-11.
  • 10王永才等.淋巴细胞微核4项指标及DNA含量对白血病早期诊断研究应用.中华误诊学杂志,2001,6(4):481-481.

共引文献71

同被引文献36

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部